

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III JAVELIN Bladder 100 trial assessing the efficacy of maintenance avelumab in patients with advanced bladder cancer who respond to front-line platinum-based chemotherapy demonstrated which outcome with avelumab?**
 - a. A significant improvement in overall survival**
 - b. No improvement in overall survival
- 2. Enfortumab vedotin, an FDA-approved agent for patients with previously treated advanced bladder cancer, belongs to which class of drugs?**
 - a. Antibody-drug conjugates**
 - b. Immune checkpoint inhibitors
 - c. Monoclonal antibodies
- 3. Erdafitinib is approved for locally advanced or metastatic urothelial bladder carcinoma (UBC) in which of the following patient populations?**
 - a. All patients with relapsed/refractory disease
 - b. Patients with a high PD-L1 expression level
 - c. Patients with relapsed/refractory disease and FGFR2 or FGFR3 genetic alterations**
- 4. Which of the following conditions is commonly associated with erdafitinib therapy for patients with metastatic UBC?**
 - a. Tinnitus
 - b. Ocular disorders**
 - c. Proteinuria
 - d. Increased appetite
- 5. Which drug type best describes the mechanism of action of sacituzumab govitecan?**
 - a. Anti-PD-1 monoclonal antibody
 - b. Anti-PD-L1 monoclonal antibody
 - c. Nectin-4-directed antibody-drug conjugate (ADC)
 - d. Trop-2-directed ADC**